In this study, Takara Bio will evaluate the effectiveness, safety, immunological tests etc. when HF 10 and ipilimumab are administered concomitantly for the treatment of unresectable or metastatic malignant melanoma. HF10 is an attenuated strain of Herpes Simplex Virus Type 1 (HSV-1) and shows a remarkable antitumor effect when injected into the cancer locus.

Takara Bio news release, January 30, 2017